Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

This study is currently recruiting participants.
Verified December 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00895271
First received: May 7, 2009
Last updated: March 14, 2014
Last verified: December 2013

May 7, 2009
March 14, 2014
May 2009
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00895271 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Establishing Fibroblast-derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

Background:

  • National Institutes of Health (NIH) researchers have been studying immune cells (white blood cells) to better understand how the human body s defense system works and adjusts or regulates itself, and how changes in this system can make a person sick.
  • To study the cells of patients who have problems with their immune systems, researchers would like to collect samples of skin cells from patients with immune system disorders and compare them with skin cells taken from healthy volunteers. By studying these cells, researchers hope to determine whether these cells can be modified to create a new kind of personalized gene therapy that would attempt to cure immune diseases in the future.

Objectives:

  • To obtain skin cells from patients with immune system disorders and from healthy volunteers for research and comparison purposes.

Eligibility:

  • Patients between the ages of 2 and 85 who have immune system disorders.
  • Healthy volunteers between the ages of 18 and 85.
  • Both groups will be selected from the eligible participants of existing NIH studies into immune system disorders.

Design:

  • Researchers may take up to two biopsies from participants arms, legs, abdomen, or back.
  • The biopsy site will be numbed with local anesthetic and cleaned before the sample is taken.
  • The punch skin biopsy needle will be inserted into the skin and rotated to remove a small circle of skin (approximately 1/4 to 3/8 of an inch across). The area will be closed with bandages or stitches, and then covered with a dressing. Any stitches will be removed in 7 to 10 days.
  • Tissue samples collected in the study will be stored for future research.

This protocol is designed as an adjunct to other NIAID IRB approved protocols that allow for genetic testing, which may include those that are screening protocols for patients with rare primary inmmnodeficiency or immunodysregulation disorders. Patients deemed of sufficient research interest after review of outside medical records, clinical evaluation, and testing may be invited to participate in this study. Healthy volunteers will also be invited to participate as a source of control samples for research testing. After consent and enrollment into this study, skin punch biopsies will be obtained to establish dermal fibroblast cell lines for research studies directed at understanding the genetic and biochemical bases of these diseases. Cell lines will also be used to investigate the utility of induced pluripotent stem cells (iPS) for lymphocyte derivation and targeted gene correction. Results with the potential to impact medical care will be relayed to the referring physicians and where applicable, patients will be referred to other appropriate NIH protocols for additional clinical evaluation and treatment. The study will enroll up to 200 patients and healthy volunteers over the next 5 years.

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Lymphohistiocytosis, Hemophagocytic
  • Common Variable Immunodeficiency
  • Severe Combined Immunodeficiency
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
Not Provided
  • INCLUSION CRITERIA:

Patients:

To be enrolled in this study, a patient must be greater than or equal to 2 years of age but not greater than 85 years of age, have a known diagnosis of primary immunodeficiency or immunodysregulation (or be a blood relative of such as patient), and be concurrently enrolled on an NIAID IRB approved protocol that includes genetic testing for disease of the immune system, such as but not limited to 05-I-0213 or 06-I-0015.

Healthy Volunteers:

To be enrolled in this study, a normal volunteer must fulfill all of the following criteria:

  • 1. Be enrolled on protocol 05-I-0213.
  • 2. Be a healthy adult of either sex and between ages of 18 years and 85 years

EXCLUSION CRITERIA:

Patients with a primary immunodeficiency or immunodysregulation disorder (or a blood relative of such a patient) are not eligible to be in this trial if:

  • 1. Platelet count less than 20,000/microL
  • 2. Patient is hemodynamically unstable because of acute bleeding.
  • 3. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study or limits the utility of the specimen to be obtained.

A Healthy Volunteer is not eligible to be in this trial if he or she fulfills any of the following criteria:

  • 1. Less than 18 years old or older than 85 years
  • 2. Weighs less than 110 pounds
  • 3. Is pregnant or breastfeeding
  • 4. Is receiving a chemotherapeutic agent(s) or has a malignancy
  • 5. Cannot avoid taking aspirin or non-steroidal anti-inflammatory medications during the 7 days preceding skin biopsy
  • 6. Have history of heart, lung, kidney disease, bleeding disorders, diabetes mellitus, chronic peripheral arterial or venous insufficiency, chronic diffuse skin conditions without uninvolved areas suitable for skin biopsy, poor skin healing, or keloid formation.
  • 7. Has been diagnosed as having viral hepatitis (B or C), human immunodeficiency virus (HIV), or a carrier for methicillin-resistant Staphylococcus aureus (MRSA)
  • 8. Hemoglobin measurement is less than 12.0 g/dL
  • 9. Platelet count less than 150,000/(micro)L
  • 10. PT greater than 15.0 seconds or PTT greater than 40 seconds
  • 11. Has a history of intravenous injection drug use or of engaging in high-risk activities for exposure to the acquired immunodeficiency syndrome (AIDS) virus.
Both
2 Years to 85 Years
Yes
Contact: Angela Wang, R.N. (301) 402-5160 angela.wang@nih.gov
Contact: Helen C Su, M.D. (301) 451-8783 hsu@mail.nih.gov
United States
 
NCT00895271
090133, 09-I-0133
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Principal Investigator: Helen C Su, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health Clinical Center (CC)
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP